Hematological Neoplasms
Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others. #leukemia #lymphoma #multiplemyeloma #Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms. The Read More
**High Risk Multiple Myeloma Solution and Chinese Expert Consensus** High risk multiple myeloma (HRMM) refers to patients with multiple myeloma whose overall survival is less than 2 to 3 years under current standard treatments. In 2024, the Chinese Society of Clinical Oncology’s Multiple Myeloma Expert Committee and the Chinese Anti-Cancer Association’s Hematologic Oncology Committee, organized by Read More
2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible Over the past few decades, there have been significant advancements in the treatment of hematologic malignancies, particularly with CAR-T cell therapy. Recently, Relma-cel (relmacabtagene autoleucel) showcased promising new data at the 2024 American Society of Clinical Read More
## Chinese Medical Team: Sequential CD20 CAR-T Therapy Outperforms Salvage Chemotherapy for CD19 CAR-T Resistant B-Cell Lymphoma Patients In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T therapy was ineffective or who relapsed shortly after initial success. While research continues to explore factors Read More